CN111606848A - A kind of preparation method of fluorodiphenyl substituted pyridine compounds - Google Patents
A kind of preparation method of fluorodiphenyl substituted pyridine compounds Download PDFInfo
- Publication number
- CN111606848A CN111606848A CN202010507040.0A CN202010507040A CN111606848A CN 111606848 A CN111606848 A CN 111606848A CN 202010507040 A CN202010507040 A CN 202010507040A CN 111606848 A CN111606848 A CN 111606848A
- Authority
- CN
- China
- Prior art keywords
- reaction
- catalyst
- crude product
- ethanol
- product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 150000003222 pyridines Chemical class 0.000 title description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 70
- 238000006243 chemical reaction Methods 0.000 claims abstract description 52
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 50
- 239000012043 crude product Substances 0.000 claims abstract description 45
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims abstract description 44
- 239000003054 catalyst Substances 0.000 claims abstract description 33
- 239000000047 product Substances 0.000 claims abstract description 29
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 25
- 238000010992 reflux Methods 0.000 claims abstract description 20
- -1 pyridine compound Chemical class 0.000 claims abstract description 19
- 150000001875 compounds Chemical class 0.000 claims abstract description 17
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000005695 Ammonium acetate Substances 0.000 claims abstract description 16
- 229940043376 ammonium acetate Drugs 0.000 claims abstract description 16
- 235000019257 ammonium acetate Nutrition 0.000 claims abstract description 16
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000000706 filtrate Substances 0.000 claims abstract description 13
- CUONGYYJJVDODC-UHFFFAOYSA-N malononitrile Chemical compound N#CCC#N CUONGYYJJVDODC-UHFFFAOYSA-N 0.000 claims abstract description 13
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 claims abstract description 9
- 235000005513 chalcones Nutrition 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims abstract description 9
- 239000002243 precursor Substances 0.000 claims abstract description 9
- DQFBYFPFKXHELB-VAWYXSNFSA-N trans-chalcone Chemical compound C=1C=CC=CC=1C(=O)\C=C\C1=CC=CC=C1 DQFBYFPFKXHELB-VAWYXSNFSA-N 0.000 claims abstract description 9
- 229940073735 4-hydroxy acetophenone Drugs 0.000 claims abstract description 7
- ZIUSEGSNTOUIPT-UHFFFAOYSA-N ethyl 2-cyanoacetate Chemical class CCOC(=O)CC#N ZIUSEGSNTOUIPT-UHFFFAOYSA-N 0.000 claims abstract description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims abstract description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims abstract description 6
- ZDVRPKUWYQVVDX-UHFFFAOYSA-N 2-(trifluoromethyl)benzaldehyde Chemical compound FC(F)(F)C1=CC=CC=C1C=O ZDVRPKUWYQVVDX-UHFFFAOYSA-N 0.000 claims abstract description 4
- 238000010438 heat treatment Methods 0.000 claims abstract 9
- 238000001914 filtration Methods 0.000 claims abstract 5
- 238000005406 washing Methods 0.000 claims abstract 5
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 72
- RGHHSNMVTDWUBI-UHFFFAOYSA-N 4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1 RGHHSNMVTDWUBI-UHFFFAOYSA-N 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- QEWHNJPLPZOEKU-UHFFFAOYSA-N 1-(2,4-difluorophenyl)ethanone Chemical compound CC(=O)C1=CC=C(F)C=C1F QEWHNJPLPZOEKU-UHFFFAOYSA-N 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims description 4
- NMTUHPSKJJYGML-UHFFFAOYSA-N 3-(trifluoromethyl)benzaldehyde Chemical compound FC(F)(F)C1=CC=CC(C=O)=C1 NMTUHPSKJJYGML-UHFFFAOYSA-N 0.000 claims description 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 2
- 230000002378 acidificating effect Effects 0.000 claims description 2
- 239000003729 cation exchange resin Substances 0.000 claims description 2
- 235000019441 ethanol Nutrition 0.000 claims 8
- 238000001704 evaporation Methods 0.000 claims 4
- 239000012451 post-reaction mixture Substances 0.000 claims 4
- 230000035755 proliferation Effects 0.000 abstract description 4
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Natural products CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 abstract description 3
- 208000032612 Glial tumor Diseases 0.000 abstract description 3
- 206010018338 Glioma Diseases 0.000 abstract description 3
- 150000008062 acetophenones Chemical class 0.000 abstract description 3
- 239000002246 antineoplastic agent Substances 0.000 abstract description 3
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 3
- 150000003935 benzaldehydes Chemical class 0.000 abstract description 3
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzenecarboxaldehyde Natural products O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 3
- 230000005764 inhibitory process Effects 0.000 abstract description 3
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract description 3
- 238000012216 screening Methods 0.000 abstract description 3
- 238000005580 one pot reaction Methods 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 abstract description 2
- OAVCWZUKQIEFGG-UHFFFAOYSA-O 2-(5-methyl-2H-tetrazol-1-ium-1-yl)-1,3-thiazole Chemical compound CC1=NN=N[NH+]1C1=NC=CS1 OAVCWZUKQIEFGG-UHFFFAOYSA-O 0.000 abstract 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 16
- 239000011541 reaction mixture Substances 0.000 description 14
- 239000012141 concentrate Substances 0.000 description 13
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 10
- 229910002092 carbon dioxide Inorganic materials 0.000 description 5
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- JRQPFAWHRORUGN-UHFFFAOYSA-N 4,6-diphenylpyridine-3-carbonitrile Chemical class N#CC1=CN=C(C=2C=CC=CC=2)C=C1C1=CC=CC=C1 JRQPFAWHRORUGN-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- HAWSQZCWOQZXHI-FQEVSTJZSA-N 10-Hydroxycamptothecin Chemical compound C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-FQEVSTJZSA-N 0.000 description 2
- HAWSQZCWOQZXHI-UHFFFAOYSA-N CPT-OH Natural products C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000013256 coordination polymer Substances 0.000 description 2
- 229920001795 coordination polymer Polymers 0.000 description 2
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000013110 organic ligand Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
- C07D213/85—Nitriles in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pyridine Compounds (AREA)
Abstract
Description
技术领域technical field
本发明涉及化合物制备技术领域,尤其涉及一种氟二苯基取代吡啶类化合物的制备方法。The invention relates to the technical field of compound preparation, in particular to a preparation method of a fluorodiphenyl substituted pyridine compound.
背景技术Background technique
有机配体与金属离子之间通过配位作用以及弱相互作用来构筑结构新颖、性能独特的配位聚合物,已经成为配位化学、超分子化学、晶体工程、材料化学领域的热点研究。利用配位化学特有的成键方式设计并合成新型配位聚合物材料,已成为配位化学与材料化学共同发展的方向。The coordination and weak interaction between organic ligands and metal ions to construct coordination polymers with novel structures and unique properties has become a hot research topic in the fields of coordination chemistry, supramolecular chemistry, crystal engineering, and materials chemistry. Designing and synthesizing new coordination polymer materials by using the unique bonding method of coordination chemistry has become a common development direction of coordination chemistry and materials chemistry.
本发明的化合物以取代苯乙酮,取代苯甲醛,丙二腈,氰乙酸乙酯,醋酸铵为原料,采用一锅法,合成4,6-二苯基-3氰基吡啶类化合物,经过MTT法测试,发现该药物对脑胶质瘤U251的增殖有很强的抑制作用,在筛选抗肿瘤药物上具有良好的应用前景。The compound of the present invention uses substituted acetophenone, substituted benzaldehyde, malononitrile, ethyl cyanoacetate, and ammonium acetate as raw materials, and adopts a one-pot method to synthesize 4,6-diphenyl-3 cyanopyridine compounds. The MTT method test showed that the drug has a strong inhibitory effect on the proliferation of glioma U251, and has a good application prospect in the screening of anti-tumor drugs.
发明内容SUMMARY OF THE INVENTION
基于背景技术存在的技术问题,本发明提出了一种氟二苯基取代吡啶类化合物的制备方法。Based on the technical problems existing in the background art, the present invention proposes a preparation method of fluorodiphenyl substituted pyridine compounds.
本发明提出的一种氟二苯基取代吡啶类化合物的制备方法,包括步骤如下:The preparation method of a kind of fluorodiphenyl substituted pyridine compound proposed by the present invention comprises the following steps:
S1在圆底烧瓶中加入NKC-9催化剂、4-羟基苯乙酮、2-三氟甲基苯甲醛、加入适量的CHCl3在氮气保护下加热回流,TLC跟踪反应,反应结束后,滤出催化剂用少量氯仿洗涤,滤液经浓缩得粗产品,再用 95%乙醇重结晶得到查尔酮前体化合物;S1 Add NKC-9 catalyst, 4-hydroxyacetophenone, 2-trifluoromethylbenzaldehyde to a round-bottomed flask, add an appropriate amount of CHCl3, heat to reflux under nitrogen protection, follow the reaction by TLC, after the reaction is over, filter out the catalyst Wash with a small amount of chloroform, and concentrate the filtrate to obtain a crude product, which is then recrystallized with 95% ethanol to obtain a chalcone precursor compound;
将上一步的产物与丙二腈、醋酸铵按照1:1:3的摩尔比加入到圆底烧瓶中,加入适量的无水乙醇在氮气保护下加热回流,TLC跟踪反应.反应结束后,浓缩的到反应后混合物,用乙酸乙酯:水=1:1萃取反应后的混合物,将乙酸乙酯蒸干得到粗品,将粗品在乙醇中重结晶得到目标产物,其名称为2-氨基-6-(4-羟基苯基)-4(2-三氟甲基苯基)-3-氰基吡啶,简称1a;The product of the previous step, malononitrile and ammonium acetate were added to a round-bottomed flask according to a molar ratio of 1:1:3, an appropriate amount of absolute ethanol was added, heated to reflux under nitrogen protection, and the reaction was followed by TLC. After the reaction was completed, concentrated to the reaction mixture, extract the reaction mixture with ethyl acetate:water=1:1, evaporate the ethyl acetate to dryness to obtain the crude product, and recrystallize the crude product in ethanol to obtain the target product, which is named 2-amino-6 -(4-Hydroxyphenyl)-4(2-trifluoromethylphenyl)-3-cyanopyridine, referred to as 1a;
S2在圆底烧瓶中加入NKC-9催化剂、4-羟基苯乙酮、3-三氟甲基苯甲醛、加入适量的CHCl3在氮气保护下加热回流,TLC跟踪反应,反应结束后,滤出催化剂用少量氯仿洗涤,滤液经浓缩得粗产品,再用 95%乙醇重结晶得到查尔酮前体化合物;S2 Add NKC-9 catalyst, 4-hydroxyacetophenone, 3-trifluoromethylbenzaldehyde to the round-bottomed flask, add an appropriate amount of CHCl3, heat to reflux under nitrogen protection, follow the reaction by TLC, after the reaction is over, filter out the catalyst Wash with a small amount of chloroform, and concentrate the filtrate to obtain a crude product, which is then recrystallized with 95% ethanol to obtain a chalcone precursor compound;
将上一步的产物与丙二腈、醋酸铵按照1:1:3的摩尔比加入到圆底烧瓶中,加入适量的无水乙醇在氮气保护下加热回流,TLC跟踪反应,反应结束后,浓缩的到反应后混合物,用乙酸乙酯:水=1:1萃取反应后的混合物,将乙酸乙酯蒸干得到粗品,将粗品在乙醇中重结晶得到目标产物,其名称为2-氨基-6-(4-羟基苯基)-4(3-三氟甲基苯基)-3-氰基吡啶,简称2a;The product of the previous step, malononitrile and ammonium acetate were added to a round-bottomed flask in a molar ratio of 1:1:3, an appropriate amount of anhydrous ethanol was added, heated to reflux under nitrogen protection, and the reaction was followed by TLC. After the reaction was completed, concentrated to the reaction mixture, extract the reaction mixture with ethyl acetate:water=1:1, evaporate the ethyl acetate to dryness to obtain the crude product, and recrystallize the crude product in ethanol to obtain the target product, which is named 2-amino-6 -(4-Hydroxyphenyl)-4(3-trifluoromethylphenyl)-3-cyanopyridine, referred to as 2a;
S3在圆底烧瓶中加入NKC-9催化剂、2,4-二氟苯乙酮、4-羟基苯甲醛、加入适量的CHCl3在氮气保护下加热回流,TLC跟踪反应,反应结束后,滤出催化剂用少量氯仿洗涤,滤液经浓缩得粗产品,再用95%乙醇重结晶得到查尔酮前体化合物;S3 Add NKC-9 catalyst, 2,4-difluoroacetophenone, 4-hydroxybenzaldehyde to a round-bottomed flask, add an appropriate amount of CHCl3, heat to reflux under nitrogen protection, follow the reaction by TLC, after the reaction is over, filter out the catalyst Wash with a small amount of chloroform, and concentrate the filtrate to obtain a crude product, which is then recrystallized with 95% ethanol to obtain a chalcone precursor compound;
将上一步的产物与丙二腈、醋酸铵按照1:1:3的摩尔比加入到圆底烧瓶中,加入适量的无水乙醇在氮气保护下加热回流,TLC跟踪反应.反应结束后,浓缩的到反应后混合物,用乙酸乙酯:水=1:1萃取反应后的混合物,将乙酸乙酯蒸干得到粗品,将粗品在乙醇中重结晶得到目标产物,其名称为2-氨基-6-(2,4-二氟苯基)-4-(4-羟基甲基苯基)-3-氰基吡啶,简称3a;The product of the previous step, malononitrile and ammonium acetate were added to a round-bottomed flask according to a molar ratio of 1:1:3, an appropriate amount of absolute ethanol was added, heated to reflux under nitrogen protection, and the reaction was followed by TLC. After the reaction was completed, concentrated to the reaction mixture, extract the reaction mixture with ethyl acetate:water=1:1, evaporate the ethyl acetate to dryness to obtain the crude product, and recrystallize the crude product in ethanol to obtain the target product, which is named 2-amino-6 -(2,4-Difluorophenyl)-4-(4-hydroxymethylphenyl)-3-cyanopyridine, referred to as 3a;
S4在圆底烧瓶中加入NKC-9催化剂、2,4-二氟苯乙酮、4-羟基苯甲醛、加入适量的CHCl3在氮气保护下加热回流,TLC跟踪反应,反应结束后,滤出催化剂用少量氯仿洗涤,滤液经浓缩得粗产品,再用 95%乙醇重结晶得到查尔酮前体化合物;将上一步的产物与氰乙酸乙酯、醋酸铵按照1:1:3的摩尔比加入到圆底烧瓶中,加入适量的无水乙醇在氮气保护下加热回流,TLC跟踪反应.反应结束后,浓缩的到反应后混合物,用乙酸乙酯:水=1:1萃取反应后的混合物,将乙酸乙酯蒸干得到粗品,将粗品在乙醇中重结晶得到目标产物,其名称为2-氨基-6-(2,4-二氟苯基)-4-(4-羟基甲基苯基)-2氧代-1,2-二氢-3氰基吡啶,简称4a。S4 Add NKC-9 catalyst, 2,4-difluoroacetophenone, 4-hydroxybenzaldehyde to a round-bottomed flask, add an appropriate amount of CHCl3, heat to reflux under nitrogen protection, follow the reaction by TLC, after the reaction is over, filter out the catalyst Wash with a small amount of chloroform, and concentrate the filtrate to obtain a crude product, which is then recrystallized with 95% ethanol to obtain a chalcone precursor compound; the product of the previous step, ethyl cyanoacetate and ammonium acetate are added in a molar ratio of 1:1:3 Into a round-bottomed flask, add an appropriate amount of anhydrous ethanol, heat to reflux under nitrogen protection, follow the reaction by TLC. After the reaction is completed, concentrate the reaction mixture, extract the reaction mixture with ethyl acetate: water = 1:1, Evaporate the ethyl acetate to dryness to obtain the crude product, and recrystallize the crude product in ethanol to obtain the target product, whose name is 2-amino-6-(2,4-difluorophenyl)-4-(4-hydroxymethylphenyl) )-2oxo-1,2-dihydro-3 cyanopyridine, referred to as 4a.
优选的,所述NKC-9催化剂为大孔强酸性苯乙烯系阳离子交换树脂。Preferably, the NKC-9 catalyst is a macroporous strongly acidic styrene-based cation exchange resin.
本发明中,所述一种氟二苯基取代吡啶类化合物的制备方法,本发明的化合物以取代苯乙酮,取代苯甲醛,丙二腈,氰乙酸乙酯,醋酸铵为原料,采用一锅法,合成4,6-二苯基-3氰基吡啶类化合物,经过MTT法测试,发现该药物对脑胶质瘤U251的增殖有很强的抑制作用,在筛选抗肿瘤药物上具有良好的应用前景。In the present invention, for the preparation method of a fluorodiphenyl substituted pyridine compound, the compound of the present invention uses substituted acetophenone, substituted benzaldehyde, malononitrile, ethyl cyanoacetate and ammonium acetate as raw materials, and adopts a The pot method was used to synthesize 4,6-diphenyl-3 cyanopyridine compounds. After the MTT method, it was found that the drug has a strong inhibitory effect on the proliferation of glioma U251, and it has a good effect in screening anti-tumor drugs. application prospects.
具体实施方式Detailed ways
下面将对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。The technical solutions in the embodiments of the present invention will be described clearly and completely below. Obviously, the described embodiments are only a part of the embodiments of the present invention, rather than all the embodiments.
实施例一Example 1
2-氨基-6-(4-羟基苯基)-4(2-三氟甲基苯基)-3-氰基吡啶其合成路线如下:The synthetic route of 2-amino-6-(4-hydroxyphenyl)-4(2-trifluoromethylphenyl)-3-cyanopyridine is as follows:
称取4-羟基苯乙酮(408mg,3mmol),2-三氟甲基苯甲醛 (522mg3mmol),0.4gNKC-9催化剂加入到圆底烧瓶中,加入5ml氯仿溶解,冲入氮气保护,回流反应,TLC监测反应进程,待反应完全后,冷却到室温,过滤出NKC-9催化剂,将滤液浓缩得到中间体的粗产物,将中间体的粗产物用95%的乙醇重结晶,得到中间体的纯品。Weigh 4-hydroxyacetophenone (408mg, 3mmol), 2-trifluoromethylbenzaldehyde (522mg3mmol), add 0.4g NKC-9 catalyst to the round-bottomed flask, add 5ml chloroform to dissolve, rush into nitrogen protection, reflux reaction , TLC monitors the reaction progress, after the reaction is complete, cool to room temperature, filter out the NKC-9 catalyst, concentrate the filtrate to obtain the crude product of the intermediate, and recrystallize the crude product of the intermediate with 95% ethanol to obtain the crude product of the intermediate. Pure.
称取中间体3mmol,丙二腈(198mg,3mmol),醋酸铵(514mg, 9mmol)加入到圆底烧瓶中,加入20ml无水乙醇,冲入氮气保护,回流反应8h,TLC监测反应进程,待反应完全,浓缩得到反应后混合物,用乙酸乙酯:水=1:1萃取反应后的混合物,将乙酸乙酯蒸干得到粗品,将粗品在乙醇中重结晶得到目标产物。Weigh intermediate 3mmol, malononitrile (198mg, 3mmol), ammonium acetate (514mg, 9mmol) were added to the round-bottomed flask, 20ml absolute ethanol was added, nitrogen protection was added, and the reaction was refluxed for 8h. After the reaction is complete, concentrate to obtain the reaction mixture, extract the reaction mixture with ethyl acetate: water = 1:1, evaporate the ethyl acetate to dryness to obtain the crude product, and recrystallize the crude product in ethanol to obtain the target product.
其名称为2-氨基-6-(4-羟基苯基)-4(2-三氟甲基苯基)-3- 氰基吡啶,简称1a,其结构式如下:Its name is 2-amino-6-(4-hydroxyphenyl)-4(2-trifluoromethylphenyl)-3-cyanopyridine, referred to as 1a, and its structural formula is as follows:
产品1a为淡黄色粉末固体(产率43%),核磁1HNMR(400MHz, DMSO-d6)δ9.97(s,1H),8.13–8.03(m,0H),8.00–7.88 (m,2H),7.82(td,J=7.8,1.3Hz,1H),7.78–7.68(m,1H), 7.64(s,0H),7.57–7.49(m,1H),7.08(s,1H),7.01(s,1H), 6.94–6.82(m,2H).13CNMR(101MHz,DMSO-d6)δ160.17, 158.42,153.36,136.55,133.12,131.36,130.01,129.39,128.64, 128.47,126.72,116.74,115.96,109.12,87.60。Product 1a is a pale yellow powder solid (yield 43%), 1HNMR (400MHz, DMSO-d6)δ9.97(s,1H), 8.13–8.03(m,0H), 8.00–7.88 (m,2H), 7.82(td, J=7.8, 1.3Hz, 1H), 7.78-7.68(m, 1H), 7.64(s, 0H), 7.57-7.49(m, 1H), 7.08(s, 1H), 7.01(s, 1H), 6.94–6.82(m, 2H).13CNMR(101MHz,DMSO-d6)δ160.17, 158.42,153.36,136.55,133.12,131.36,130.01,129.39,128.64, 128.47,126.72,116.74,115 87.60.
实例二Example 2
2-氨基-6-(4-羟基苯基)-4(3-三氟甲基苯基)-3-氰基吡啶2-Amino-6-(4-hydroxyphenyl)-4(3-trifluoromethylphenyl)-3-cyanopyridine
其合成路线如下:Its synthetic route is as follows:
称取4-羟基苯乙酮(408mg,3mmol),3-三氟甲基苯甲醛 (522mg3mmol),0.4gNKC-9催化剂加入到圆底烧瓶中,加入5ml氯仿溶解,冲入氮气保护,回流反应,TLC监测反应进程,待反应完全后,冷却到室温,过滤出NKC-9催化剂,将滤液浓缩得到中间体的粗产物,将中间体的粗产物用95%的乙醇重结晶,得到中间体的纯品。4-Hydroxyacetophenone (408mg, 3mmol), 3-trifluoromethylbenzaldehyde (522mg3mmol), 0.4g NKC-9 catalyst were weighed into the round-bottomed flask, 5ml of chloroform was added to dissolve, flushed into nitrogen protection, and refluxed for reaction , TLC monitors the reaction progress, after the reaction is complete, cool to room temperature, filter out the NKC-9 catalyst, concentrate the filtrate to obtain the crude product of the intermediate, and recrystallize the crude product of the intermediate with 95% ethanol to obtain the crude product of the intermediate. Pure.
称取中间体3mmol,丙二腈(198mg,3mmol),醋酸铵(514mg, 9mmol)加入到圆底烧瓶中,加入20ml无水乙醇,冲入氮气保护,回流反应8h,TLC监测反应进程,待反应完全,浓缩得到反应后混合物,用乙酸乙酯:水=1:1萃取反应后的混合物,将乙酸乙酯蒸干得到粗品,将粗品在乙醇中重结晶得到目标产物。Weigh intermediate 3mmol, malononitrile (198mg, 3mmol), ammonium acetate (514mg, 9mmol) were added to the round-bottomed flask, 20ml absolute ethanol was added, nitrogen protection was added, and the reaction was refluxed for 8h. After the reaction is complete, concentrate to obtain the reaction mixture, extract the reaction mixture with ethyl acetate: water = 1:1, evaporate the ethyl acetate to dryness to obtain the crude product, and recrystallize the crude product in ethanol to obtain the target product.
其名称为2-氨基-6-(4-羟基苯基)-4(3-三氟甲基苯基)-3- 氰基吡啶,简称2a,其结构式如下:Its name is 2-amino-6-(4-hydroxyphenyl)-4(3-trifluoromethylphenyl)-3-cyanopyridine, referred to as 2a, and its structural formula is as follows:
产品2a为淡黄色固体(产率42%),核磁1HNMR(400MHz, DMSO-d6)δ9.97(s,1H),8.08–7.96(m,4H),7.94–7.88 (m,1H),7.80(t,J=7.8Hz,1H),7.27(s,1H),7.01(s,2H),6.90–6.85(m,2H)。Product 2a is a pale yellow solid (yield 42%), 1HNMR (400MHz, DMSO-d6)δ9.97(s,1H), 8.08–7.96(m,4H), 7.94–7.88 (m,1H), 7.80 (t, J=7.8 Hz, 1H), 7.27 (s, 1H), 7.01 (s, 2H), 6.90–6.85 (m, 2H).
13CNMR(101MHz,DMSO-d6)δ161.20,160.15,159.38, 138.60,133.04,130.32,129.56,128.87,128.67,126.57(d,J =3.9Hz),125.53(d,J=4.0Hz),117.54,115.86,108.74,85.62。13CNMR(101MHz,DMSO-d6)δ161.20,160.15,159.38,138.60,133.04,130.32,129.56,128.87,128.67,126.57(d,J=3.9Hz),125.53(d,J=4.0Hz),117.54,115 108.74, 85.62.
实例三Example three
2-氨基-6-(2,4-二氟苯基)-4-(4-羟基甲基苯基)-3-氰基吡啶;2-amino-6-(2,4-difluorophenyl)-4-(4-hydroxymethylphenyl)-3-cyanopyridine;
其合成路线如下:Its synthetic route is as follows:
称取2,4-二氟苯乙酮(408mg,3mmol),4-羟基苯甲醛 (522mg3mmol),0.4gNKC-9催化剂加入到圆底烧瓶中,加入5ml氯仿溶解,冲入氮气保护,回流反应,TLC监测反应进程,待反应完全后,冷却到室温,过滤出NKC-9催化剂,将滤液浓缩得到中间体的粗产物,将中间体的粗产物用95%的乙醇重结晶,得到中间体的纯品。Weigh 2,4-difluoroacetophenone (408mg, 3mmol), 4-hydroxybenzaldehyde (522mg3mmol), add 0.4g NKC-9 catalyst to the round bottom flask, add 5ml chloroform to dissolve, flush with nitrogen protection, reflux reaction , TLC monitors the reaction progress, after the reaction is complete, cool to room temperature, filter out the NKC-9 catalyst, concentrate the filtrate to obtain the crude product of the intermediate, and recrystallize the crude product of the intermediate with 95% ethanol to obtain the crude product of the intermediate. Pure.
称取中间体3mmol,丙二腈(198mg,3mmol),醋酸铵(514mg, 9mmol)加入到圆底烧瓶中,加入20ml无水乙醇,冲入氮气保护,回流反应8h,TLC监测反应进程,待反应完全,浓缩得到反应后混合物,用乙酸乙酯:水=1:1萃取反应后的混合物,将乙酸乙酯蒸干得到粗品,将粗品在乙醇中重结晶得到目标产物。Weigh intermediate 3mmol, malononitrile (198mg, 3mmol), ammonium acetate (514mg, 9mmol) were added to the round-bottomed flask, 20ml absolute ethanol was added, nitrogen protection was added, and the reaction was refluxed for 8h. After the reaction is complete, concentrate to obtain the reaction mixture, extract the reaction mixture with ethyl acetate: water = 1:1, evaporate the ethyl acetate to dryness to obtain the crude product, and recrystallize the crude product in ethanol to obtain the target product.
其名称为2-氨基-6-(2,4-二氟苯基)-4-(4-羟基甲基苯基) -3-氰基吡啶,简称3a,其结构式如下:Its name is 2-amino-6-(2,4-difluorophenyl)-4-(4-hydroxymethylphenyl)-3-cyanopyridine, referred to as 3a, and its structural formula is as follows:
产品3a为白色固体(产率40%),核磁1HNMR(400MHz,DMSO-d6) δ10.00(d,J=1.3Hz,1H),8.06–7.80(m,1H),7.51(dd, J=8.4,1.6Hz,2H),7.39(ddd,J=11.7,9.2,2.4Hz,1H), 7.26(td,J=8.5,2.3Hz,1H),7.10–6.98(m,3H),6.99– 6.87(m,2H).13CNMR(101MHz,DMSO-d6)δ161.38,159.52, 155.10,154.50,133.52–131.96(m),130.24,127.60,124.05 –122.29(m),117.58,116.08,113.30–112.19(m),105.22(t, J=26.8Hz),87.21。Product 3a is a white solid (yield 40%), 1H NMR (400MHz, DMSO-d6) δ10.00 (d, J=1.3Hz, 1H), 8.06-7.80 (m, 1H), 7.51 (dd, J= 8.4, 1.6Hz, 2H), 7.39 (ddd, J=11.7, 9.2, 2.4Hz, 1H), 7.26 (td, J=8.5, 2.3Hz, 1H), 7.10–6.98 (m, 3H), 6.99– 6.87 (m,2H).13CNMR(101MHz,DMSO-d6)δ161.38,159.52,155.10,154.50,133.52–131.96(m),130.24,127.60,124.05–122.29(m),117.58,116.08,113.30–112.19(m) , 105.22(t, J=26.8Hz), 87.21.
实例四Example 4
2-氨基-6-(2,4-二氟苯基)-4-(4-羟基甲基苯基)-2氧代-1,2- 二氢-3氰基吡啶2-Amino-6-(2,4-difluorophenyl)-4-(4-hydroxymethylphenyl)-2oxo-1,2-dihydro-3cyanopyridine
去合成路线如下:The synthetic route is as follows:
称取2,4-二氟苯乙酮(408mg,3mmol),4-羟基苯甲醛 (522mg3mmol),0.4gNKC-9催化剂加入到圆底烧瓶中,加入5ml氯仿溶解,冲入氮气保护,回流反应,TLC监测反应进程,待反应完全后,冷却到室温,过滤出NKC-9催化剂,将滤液浓缩得到中间体的粗产物,将中间体的粗产物用95%的乙醇重结晶,得到中间体的纯品Weigh 2,4-difluoroacetophenone (408mg, 3mmol), 4-hydroxybenzaldehyde (522mg3mmol), add 0.4g NKC-9 catalyst to the round bottom flask, add 5ml chloroform to dissolve, flush with nitrogen protection, reflux reaction , TLC monitors the reaction progress, after the reaction is complete, cool to room temperature, filter out the NKC-9 catalyst, concentrate the filtrate to obtain the crude product of the intermediate, and recrystallize the crude product of the intermediate with 95% ethanol to obtain the crude product of the intermediate. Pure
称取中间体3mmol,氰乙酸乙酯(340mg,3mmol),醋酸铵(514mg, 9mmol)加入到圆底烧瓶中,加入20ml无水乙醇,冲入氮气保护,回流反应8h,TLC监测反应进程,待反应完全,浓缩得到反应后混合物,用乙酸乙酯:水=1:1萃取反应后的混合物,将乙酸乙酯蒸干得到粗品,将粗品在乙醇中重结晶得到目标产物。Weighing intermediate 3mmol, ethyl cyanoacetate (340mg, 3mmol), ammonium acetate (514mg, 9mmol) were added to the round-bottomed flask, 20ml of absolute ethanol was added, nitrogen protection was added, the reaction was refluxed for 8h, and the reaction progress was monitored by TLC, After the reaction is complete, concentrate to obtain the reacted mixture, extract the reacted mixture with ethyl acetate:water=1:1, evaporate the ethyl acetate to dryness to obtain the crude product, and recrystallize the crude product in ethanol to obtain the target product.
其名称为2-氨基-6-(2,4-二氟苯基)-4-(4-羟基甲基苯基) -2氧代-1,2-二氢-3氰基吡啶,简称4a,其结构式如下:Its name is 2-amino-6-(2,4-difluorophenyl)-4-(4-hydroxymethylphenyl)-2oxo-1,2-dihydro-3 cyanopyridine, referred to as 4a , and its structure is as follows:
产品4a为白色固体(产率45%),核磁1HNMR(400MHz,DMSO-d6) δ12.77(s,1H),10.18(s,1H),7.81(td,J=8.6,6.4Hz,1H), 7.71–7.58(m,2H),7.49(ddd,J=11.4,9.3,2.5Hz,1H), 7.28(td,J=8.5,2.6Hz,1H),7.05–6.89(m,2H),6.63(s, 1H).13CNMR(101MHz,DMSO-d6)δ165.38(d,J=12.7Hz), 162.89(d,J=12.4Hz),162.19,161.36(d,J=12.9Hz),160.40, 158.84(d,J=13.0Hz),132.95(dd,J=10.4,3.5Hz),130.62, 126.49,118.42,117.23,116.09,112.69(dd,J=21.7,3.5Hz), 108.68,105.36(t,J=26.2Hz),98.61。Product 4a is a white solid (yield 45%), nuclear magnetic 1HNMR (400MHz, DMSO-d6) δ12.77 (s, 1H), 10.18 (s, 1H), 7.81 (td, J=8.6, 6.4Hz, 1H) , 7.71–7.58(m, 2H), 7.49(ddd, J=11.4, 9.3, 2.5Hz, 1H), 7.28(td, J=8.5, 2.6Hz, 1H), 7.05–6.89(m, 2H), 6.63 (s, 1H).13CNMR(101MHz,DMSO-d6)δ165.38(d,J=12.7Hz), 162.89(d,J=12.4Hz),162.19,161.36(d,J=12.9Hz),160.40, 158.84(d, J=13.0Hz), 132.95(dd, J=10.4, 3.5Hz), 130.62, 126.49, 118.42, 117.23, 116.09, 112.69(dd, J=21.7, 3.5Hz), 108.68, 105.36(t, J=26.2Hz), 98.61.
双苯基吡啶类化合物1-4的抗肿瘤效果;Antitumor effect of biphenylpyridine compounds 1-4;
选择u251为靶细胞,用10-羟基喜树碱为阳性药,用MTT比色法测定细胞的抗增殖效果。取0.25%胰蛋白酶消化单层培养的u251 细胞,用含有10%的胎牛血清的DEME培养基调成每毫升1*105的单细胞悬浮液,以每孔100ul接种于96孔板中。Select u251 as the target cell, use 10-hydroxycamptothecin as the positive drug, and measure the antiproliferative effect of the cells by MTT colorimetry. Take 0.25% trypsinized monolayer cultured u251 cells, adjust with DEME medium containing 10% fetal bovine serum to make a single cell suspension of 1*105 per ml, and inoculate 100ul per well in a 96-well plate.
培养板放入二氧化碳CO2培养箱,37℃,5%CO2饱和湿度条件下培养24h,待细胞贴壁后,吸出旧的培养基,分别加入含有40uM、20uM、 10uM、5uM、2.5uM待测药物和5%胎牛血清的培养基(),每个浓度设置设置5个复孔,实验设置空白组,继续放入CO2培养箱,37℃,5% CO2饱和湿度条件下培养48h;之后吸出培养基,每孔加入MTT(5mg/L) 20ul,继续放入CO2培养箱,37℃,5%CO2饱和湿度条件下培养1h;加入DMSO100ul,震荡溶解甲瓒沉淀,在酶联免疫检测仪上测定490nm 测量各个孔的吸光度(A)值,按公式:抑制率=(阴性对照组平均A值-给药组平均A值)/(对照组平均A值-空白对照组A值)*100%。The culture plate was placed in a carbon dioxide CO2 incubator, and incubated at 37°C under 5% CO2 saturated humidity conditions for 24 hours. After the cells adhered, the old medium was sucked out, and 40uM, 20uM, 10uM, 5uM, 2.5uM of the drug to be tested were added respectively. and 5% fetal bovine serum (FBS), 5 replicate wells were set for each concentration setting, and the experiment was set up as a blank group, and continued to be placed in a CO2 incubator, 37°C, and 5% CO2-saturated humidity for 48 hours; then aspirated and cultured base, add 20ul MTT (5mg/L) to each well, continue to put it in a CO2 incubator, incubate at 37°C, 5% CO2-saturated humidity for 1 h; add 100ul DMSO, shake to dissolve the formazan precipitate, and measure it on an enzyme-linked immunosorbent assay (ELISA) Measure the absorbance (A) value of each well at 490 nm, according to the formula: inhibition rate=(average A value of negative control group-average A value of administration group)/(average A value of control group-A value of blank control group)*100%.
计算化合物对细胞的抑制率Calculate the rate of inhibition of cells by compounds
表中为4,6-二苯基-3氰基吡啶类化合物抗肿瘤增殖活性The table shows the anti-tumor proliferation activity of 4,6-diphenyl-3 cyanopyridine compounds
以上所述,仅为本发明较佳的具体实施方式,但本发明的保护范围并不局限于此,任何熟悉本技术领域的技术人员在本发明揭露的技术范围内,根据本发明的技术方案及其发明构思加以等同替换或改变,都应涵盖在本发明的保护范围之内。The above description is only a preferred embodiment of the present invention, but the protection scope of the present invention is not limited to this. The equivalent replacement or change of the inventive concept thereof shall be included within the protection scope of the present invention.
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010507040.0A CN111606848A (en) | 2020-06-05 | 2020-06-05 | A kind of preparation method of fluorodiphenyl substituted pyridine compounds |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010507040.0A CN111606848A (en) | 2020-06-05 | 2020-06-05 | A kind of preparation method of fluorodiphenyl substituted pyridine compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111606848A true CN111606848A (en) | 2020-09-01 |
Family
ID=72198454
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010507040.0A Pending CN111606848A (en) | 2020-06-05 | 2020-06-05 | A kind of preparation method of fluorodiphenyl substituted pyridine compounds |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111606848A (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102827073A (en) * | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | Therapeutically active compositions and application methods thereof |
CN102838536A (en) * | 2012-09-25 | 2012-12-26 | 中国林业科学研究院林产化学工业研究所 | 3-cyanopyridine derivative and preparation as well as application thereof |
CN102875462A (en) * | 2012-10-11 | 2013-01-16 | 中国药科大学 | Anti-tumor 2-amino nicotinonitrile, application and preparation method thereof |
CN103804160A (en) * | 2014-01-27 | 2014-05-21 | 南京运华立太能源科技有限公司 | Preparation method of 3-methyl-3-amylene-2-ketone |
CN109020883A (en) * | 2018-03-27 | 2018-12-18 | 广西民族大学 | A kind of 3- cyano -2-aminopyridine analog derivative and the preparation method and application thereof |
CN109651341A (en) * | 2017-10-11 | 2019-04-19 | 上海医药工业研究院 | Phonetic (pyrrole) the pyridine analog derivative of dimorpholine cyano and as anti-tumor drug application |
-
2020
- 2020-06-05 CN CN202010507040.0A patent/CN111606848A/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102827073A (en) * | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | Therapeutically active compositions and application methods thereof |
CN102838536A (en) * | 2012-09-25 | 2012-12-26 | 中国林业科学研究院林产化学工业研究所 | 3-cyanopyridine derivative and preparation as well as application thereof |
CN102875462A (en) * | 2012-10-11 | 2013-01-16 | 中国药科大学 | Anti-tumor 2-amino nicotinonitrile, application and preparation method thereof |
CN103804160A (en) * | 2014-01-27 | 2014-05-21 | 南京运华立太能源科技有限公司 | Preparation method of 3-methyl-3-amylene-2-ketone |
CN109651341A (en) * | 2017-10-11 | 2019-04-19 | 上海医药工业研究院 | Phonetic (pyrrole) the pyridine analog derivative of dimorpholine cyano and as anti-tumor drug application |
CN109020883A (en) * | 2018-03-27 | 2018-12-18 | 广西民族大学 | A kind of 3- cyano -2-aminopyridine analog derivative and the preparation method and application thereof |
Non-Patent Citations (1)
Title |
---|
AYA M. SERRY 等: ""One-Pot Synthesis of 4,6-Diaryl-2-oxo(imino)-1,2-dihydropyridine-3-carbonitrile; a New Scaffold for p38αMAP Kinase Inhibition"", 《J. COMB. CHEM.》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101941919B (en) | Method for preparing derivatives of cis-oximes and oxime ethers | |
CN103608341B (en) | N-aryl unsaturated condensed ring tertiary amine compounds and preparation method thereof and antitumor application | |
CN109438365B (en) | N- (3- ((4-trifluoromethyl) -2-pyrimidinyl) aminophenyl) -2, 6-difluorobenzenesulfonamide derivative | |
CN113387892B (en) | Imidazole heterocyclic derivative containing nitrogen mustard and preparation method and application thereof | |
CN109970679B (en) | Paeonol thiazole derivatives and preparation method and application thereof | |
JPH04210946A (en) | Novel aryl vinylamide derivative and method for producing the same | |
CN111606848A (en) | A kind of preparation method of fluorodiphenyl substituted pyridine compounds | |
KR100830541B1 (en) | Novel Chalcone Derivatives with Interleukin-5 Inhibitory Effect | |
CN107573336B (en) | Benzoheterocycle-formamide-pyridone derivative and preparation method and application thereof | |
CN109020883B (en) | A kind of 3-cyano-2-aminopyridine derivative and its preparation method and application | |
CN110483465B (en) | Synthesis method of genistein bridged piperazine derivatives and application of genistein bridged piperazine derivatives in anti-tumor direction | |
CN101555248B (en) | Method for preparing poly-substituted 1, 5-naphthyridine compound | |
CN105541715A (en) | Polysubstituted pyridine-1 (2H) -ketone derivative and synthetic method and application thereof | |
Ivachtchenko et al. | Synthesis and Biological Evaluation of Novel 5, 8‐Disubstituted‐2‐methyl‐2, 3, 4, 5‐tetrahydro‐1H‐pyrido [4, 3‐b] indoles as 5‐HT6 and H1 Receptors Antagonists | |
JPS59190974A (en) | Production of 5-carbamoyl-6-methyl-4-substituted-1,2,3,4- tetrahydro-2-thioxopyrimidine | |
CN110872263A (en) | A compound and preparation method and application | |
CN106866680B (en) | A kind of 3- aryl-6-carboxyamide pyrazoles simultaneously [1,5-a] pyrimidines and its application | |
CN112250639B (en) | Heterocyclic substituted arylamine compound and preparation method and application thereof | |
CN114560855B (en) | Cycloalkyl carboxamide derivatives, preparation method and application thereof | |
CN109438358A (en) | A kind of imdazole derivatives and application thereof | |
CN112028955B (en) | Trimethoxylated arabinose triazole structure spiroisoxazole-pyrrolizine derivative and preparation method and application thereof | |
CN117603127A (en) | Novel chalcone derivative containing nitrogen heterocycle, and preparation method and application thereof | |
CN108707153B (en) | D-valine substituted maleimide derivative and preparation method and application thereof | |
CN109160902B (en) | Asymmetric bisquinazoline Schiff base derivative for treating tumors and preparation and medical application thereof | |
CN107382941B (en) | Flavone derivative and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Shen Liqun Inventor after: Lu Jiahao Inventor after: Wu Aiqun Inventor after: Lei Fuhou Inventor after: Yao Xingdong Inventor after: Li Wen Inventor after: Yang Jun Inventor after: Lai Wuji Inventor after: Qi Wanling Inventor before: Shen Liqun Inventor before: Wu Aiqun Inventor before: Lu Jiahao Inventor before: Lei Fuhou Inventor before: Yao Xingdong Inventor before: Li Wen Inventor before: Yang Jun Inventor before: Lai Wuji Inventor before: Qi Wanling |
|
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200901 |